GLP-1 and Thyroid: What the Research Actually Says

The thyroid concern with GLP-1 medications stems from a specific rodent finding: in rat and mouse studies, GLP-1 receptor agonists caused C-cell hyperplasia and medullary thyroid carcinoma (MTC) at doses far above the therapeutic range. This was discovered during pre-clinical development and has been on the prescribing information for semaglutide and liraglutide since they launched.

What followed was years of human monitoring. The question was whether the rodent signal translated to humans. The answer, based on the accumulated evidence, is that it does not. At least not detectably, and not at therapeutic doses.

Understanding the distinction between the rodent data, the human evidence, and what thyroid monitoring on GLP-1 is actually for matters if you want to make sense of the standard prescribing information.

The Rodent Finding: What It Was

In pre-clinical carcinogenicity studies, rats and mice given GLP-1 receptor agonists developed C-cell hyperplasia (abnormal proliferation of parafollicular C-cells in the thyroid) and medullary thyroid carcinoma at high doses. This finding was consistent across multiple GLP-1 agonists and was dose-dependent.

Medullary thyroid carcinoma is a cancer of the parafollicular C-cells, which produce calcitonin. It accounts for approximately 4% of all thyroid cancers and is rare in the general population.

The concerning aspect of the rodent finding: it was consistent and biologically plausible. Rodent C-cells express GLP-1 receptors at higher density than human C-cells, making them more susceptible to GLP-1-driven proliferation.

The mitigating context: rodents were given doses far above therapeutic ranges. Rat thyroid biology differs from human thyroid biology in ways that affect whether this translates. Rodents are known to be more sensitive than humans to GLP-1 receptor stimulation in C-cells specifically.

The Human Evidence: What It Shows

The FDA and EMA required extensive human monitoring as part of GLP-1 drug approvals. The accumulated data from clinical trials and post-marketing surveillance now covers millions of patient-years of exposure.

A 2023 pharmacovigilance study using real-world data from France found a modest increased signal for thyroid cancer in GLP-1 users compared to non-users. This generated headlines. However, multiple methodological limitations (comparator selection bias, confounding by obesity as itself a thyroid cancer risk factor, and absence of MTC-specific data) meant the study was not considered sufficient to change the risk assessment.

The EMA completed a review in 2024 and maintained that the benefit-risk profile of GLP-1 receptor agonists remains favourable. No causal link between therapeutic doses of GLP-1 agonists and medullary thyroid carcinoma has been established in humans.

Absolute Contraindications

The prescribing information for all GLP-1 receptor agonists includes absolute contraindications that remain in place regardless of the overall human evidence:

Medullary thyroid carcinoma (MTC): Personal history of MTC is a contraindication. GLP-1 therapy is not appropriate for people who have had MTC.

Multiple Endocrine Neoplasia type 2 (MEN2): MEN2 is a genetic syndrome that predisposes to MTC. GLP-1 is contraindicated.

Family history of MTC: First-degree family history of MTC is a relative contraindication. Discuss with your prescriber before starting.

If you are in any of these groups and have been prescribed GLP-1, raise this explicitly with your prescriber. It should have been covered at initiation but confirm it has.

What Thyroid Monitoring Is Actually For

Given that the MTC concern is not confirmed in human data, what is the purpose of TSH monitoring on GLP-1?

Two reasons.

First, confounding. Hypothyroidism (underactive thyroid) and hyperthyroidism both affect metabolism, weight, and energy: all the outcomes that GLP-1 monitoring is tracking. An undiagnosed thyroid problem can look like a suboptimal GLP-1 response. If someone loses less weight than expected on GLP-1, knowing their thyroid function rules out a confounding cause.

Second, baseline for comparison. GLP-1 medications cause significant metabolic changes. Having a pre-treatment TSH confirms your thyroid was functioning normally before you started, so any future thyroid issue can be attributed appropriately rather than assumed to be pre-existing.

The monitoring is not primarily to catch MTC, which is diagnosed by calcitonin and imaging, not TSH. TSH monitors general thyroid function. Calcitonin monitoring is optional in most UK prescribing protocols, though some prescribers include it at baseline.

Understanding TSH Results

TSH (thyroid-stimulating hormone) is produced by the pituitary gland and drives thyroid hormone production. It is the primary screening test for thyroid function.

Normal range: 0.4–4.0 mIU/L (varies slightly by lab and age).

Elevated TSH (above 4.0 mIU/L): Suggests hypothyroidism. The thyroid is underactive and the pituitary is compensating by increasing TSH output. Hypothyroidism causes fatigue, weight gain, cold intolerance, and slowed metabolism. On GLP-1, undiagnosed hypothyroidism would reduce the medication's apparent efficacy.

Suppressed TSH (below 0.4 mIU/L): Suggests hyperthyroidism or subclinical hyperthyroidism. The thyroid is overactive. Causes weight loss, rapid heart rate, anxiety, and heat intolerance. Hyperthyroidism might artificially inflate apparent GLP-1 weight loss.

Free T4 and free T3: If TSH is outside range, these confirm whether the abnormal TSH represents true thyroid dysfunction and quantify the degree.

Calcitonin: The MTC Marker

Calcitonin is produced by thyroid C-cells. Elevated calcitonin is the primary marker for MTC. It was elevated in virtually all MTC cases in the pre-clinical rodent data and is the clinical marker used in humans to screen for and monitor MTC.

Some prescribers and guidelines recommend baseline calcitonin measurement before starting GLP-1. The NICE guidelines in the UK do not currently mandate this for the general population without MTC risk factors, but it is reasonable to request.

A calcitonin above 10–20 pg/mL at baseline warrants further investigation, irrespective of GLP-1 use. Values consistently below 10 pg/mL are reassuring.

If you have a thyroid nodule discovered incidentally (for example on imaging done for another reason), calcitonin testing before starting GLP-1 is worth discussing with your GP.

The Testing Schedule

Before starting GLP-1: TSH (and free T4 if TSH is borderline). Calcitonin if you have risk factors (nodule, family history, MEN2 concern). This is your baseline.

At 6 months: TSH repeat. By this point any weight loss and metabolic changes should be established. A 6-month TSH confirms your thyroid function is stable.

Annually: TSH as part of your annual comprehensive panel. TSH is a low-cost, low-effort addition to any blood panel and provides ongoing thyroid status confirmation.

If you develop new symptoms: Any new symptoms consistent with thyroid dysfunction (unexplained fatigue, weight change independent of GLP-1 effect, palpitations, heat or cold intolerance): test TSH regardless of where you are in the monitoring schedule. Thyroid problems can emerge at any time and are unrelated to GLP-1.

For the full blood test guide, see /guides/glp1-blood-test-panel-uk.

Correcting the Misinformation

The GLP-1-thyroid story gets routinely distorted in two directions.

One direction overstates the risk: citing the rodent data without explaining the mechanistic differences between rodent and human C-cells, the doses used, or the lack of confirmed human signal. This creates unnecessary anxiety.

The opposite direction dismisses monitoring entirely: "the thyroid concern is just from rodents, don't worry about it." This misses the legitimate clinical reasons for TSH monitoring (confounding, baseline establishment) and ignores that the contraindications for MTC history and MEN2 are real and important.

The accurate position is more boring than either extreme: GLP-1 medications have not been shown to cause thyroid cancer in humans at therapeutic doses. They remain contraindicated in people with MTC history or MEN2. Thyroid monitoring is clinically useful for reasons largely unrelated to the rodent MTC concern. TSH at baseline and at 6 months is standard practice and takes 60 seconds to add to a blood draw.

For a more detailed discussion of the thyroid-GLP-1 data and the historical regulatory story, see /guides/ozempic-and-thyroid-uk. For the broader side effects context, see /guides/glp1-side-effects-uk.

The Summary

The thyroid story on GLP-1 is: rodent signal does not translate to confirmed human risk at therapeutic doses. Contraindications for MTC history and MEN2 remain. TSH monitoring is good practice for metabolic context and baseline establishment, not primarily for MTC screening. Calcitonin is worth adding at baseline if you have risk factors.

Monitor thyroid function as part of your standard panel. Know the contraindications. And treat any online headline claiming GLP-1 drugs "cause thyroid cancer" with appropriate scepticism: the evidence does not support it.